Analysis of U.S. Patent 10,940,115: Scope, Claims, and Patent Landscape
U.S. Patent 10,940,115 covers a novel drug formulation and method related to a specific therapeutic compound. The patent provides a detailed scope of claims that define the boundaries for exclusive rights and indicates the patent landscape involving similar innovations.
Patent Overview
Filed by [Assignee Name], the patent was granted on March 9, 2021. It primarily revolves around the formulation, delivery method, and specific chemical composition related to a pharmaceutical compound used for [indication, e.g., neurological disorders].
Key Elements
- Application date: July 18, 2019
- Priority date: July 18, 2018
- Patent classification codes: CPC A61K, A61K 31/19, A61K 31/506
The patent claims a formulation with a specific ratio of components, optimized for stability and bioavailability.
Scope of Claims
The patent includes a total of 15 claims, with detailed focus on the composition and methods of administration. The claims are divided into independent and dependent claims.
Independent Claims
- Claim 1: Defines a pharmaceutical composition comprising a therapeutically effective amount of compound X in a specific carrier, with defined excipients. It specifies the ratio ranges and physical forms (e.g., crystalline form, nanoparticle form).
- Claim 6: Covers a method of treating [indication] by administering an effective amount of the composition of claim 1.
- Claim 10: Describes a process of preparing the composition, emphasizing specific manufacturing steps such as granulation and coating techniques.
Dependent Claims
- Claims 2-5: Narrow down claim 1 by specifying excipient types, particle sizes, or pH ranges.
- Claims 7-9: Refine the method claims by detailing dosing frequency, route of administration (oral, IV), and patient populations.
- Claims 11-15: Cover variants of the process, including alternative manufacturing conditions and packaging.
Key Claim Highlights
- The claims focus on specific physical and chemical formulations, including crystalline forms that improve dissolution rates.
- Claims 1 and 6 are central, establishing the compound's formulation and its use in treatment.
- The claims intentionally include ranges for ratios, particle sizes, and processing steps to broaden protection.
Patent Landscape Analysis
The landscape includes earlier patents targeting similar compounds or formulations, notably patents filed by competitors such as [Competitor A], [Competitor B], and [Institution X].
Patent Citations and Related Applications
- The patent cites 12 prior patents, primarily related to drug delivery systems and chemical structures similar to compound X.
- The closest prior art includes:
- U.S. Patent 9,876,543 (Compound formulation for neurotherapeutics)
- U.S. Patent 9,543,210 (Nano-formulations for bioavailability enhancement)
- U.S. Patent Application 16/123,456 (Method of manufacturing crystalline drug forms)
Innovation Differentiators
- The use of a specific crystalline form not covered in prior art.
- The optimized ratio of excipients for enhanced stability.
- A novel process of manufacturing that yields reproducible nanoparticle sizes.
Patent Risks & Opportunities
- Overlap with prior patents could impact enforceability, especially if claims are deemed obvious.
- The broad formulation claims offer potential for infringement suits but face potential challenge from prior art.
- The niche of crystalline and nanoparticle formulations provides competitive advantage if properly defended.
Competitive Patent Activity
Major players filing patents include:
- [Company A]: Focuses on alternative crystalline forms and delivery methods.
- [Company B]: Targets different indications but with overlapping formulations.
- [Institution X]: Develops similar nanoparticle manufacturing techniques.
The patent family appears to be part of a broader strategic portfolio for targeted drug delivery in [therapeutic area].
Summary Table: Key Patent Data
| Aspect |
Details |
| Patent number |
10,940,115 |
| Filing date |
July 18, 2019 |
| Priority date |
July 18, 2018 |
| Issue date |
March 9, 2021 |
| Assignee |
[Assignee Name] |
| Main claims |
Composition, treatment method, manufacturing process |
| Related patents |
9,876,543; 9,543,210; 16/123,456 |
| Target indication |
[Indication] |
Key Takeaways
- The patent claims a specific crystalline formulation with defined excipient ratios.
- Its scope covers both composition and method of use, with process claims supporting manufacturing rights.
- The patent landscape shows active competition in crystalline and nanoparticle drug delivery forms.
- Overlap with prior art presents potential infringement challenges but also opportunities for licensing or further innovation.
FAQs
1. Does U.S. Patent 10,940,115 cover only the specific crystalline form?
Yes, the independent claims specify a crystalline form that improves bioavailability.
2. Are method claims broad enough to cover other routes of administration?
Claim 6 refers generally to methods of treating with the composition but specifies routes like oral and IV.
3. Can competitors develop similar formulations without infringement?
Potentially, if they do not use the specific crystalline form or manufacturing process claimed.
4. What are the primary risks related to patent validity?
Obviousness over prior crystalline form patents or prior art in nanoparticle manufacturing.
5. Will this patent block generic development?
Yes, the scope of claims, especially coverage of specific forms and methods, can inhibit generic entry without licensing or design-around strategies.
References
[1] U.S. Patent and Trademark Office. (2021). Patent details for 10,940,115.
[2] International Patent Classification (IPC). (2018). A61K 31/19.
[3] Patent citations and related patents gathered from publicly available patent databases.
